As NORD’s exclusive CME partner, Medlive brings together renowned clinicians, advocacy partners, and patients for in-depth panel discussions and programming.
Medlive will present two educational posters at the 2025 NORD Breakthrough Summit, underscoring our commitment to advancing rare disease education in collaboration with trusted partners.
Partnering for Education at a Turning Point in the Desmoid Tumor Landscape
Supported by Springworks and delivered in collaboration with NORD through the Rare Heme Series, this poster highlights how aligned partnerships ensure timely education at a pivotal moment in the desmoid tumor landscape, shaping awareness and supporting informed decision-making for patients and providers.
Challenges in PNH and CAD Management Revealed Through Educational Interventions over Three Years
Building on its debut at ASH 2024, this encore poster shares insights into the evolving challenges of paroxysmal nocturnal hemoglobinuria (PNH) and cold agglutinin disease (CAD). Supported by Apellis Pharmaceuticals (PNH) and Sanofi (CAD), and delivered in partnership with NORD through the Rare Heme Series, the program reflects the value of sustained education over multiple years and the impact of consistent, evidence-based messaging.
By highlighting these programs, Medlive reinforces its position as the CME partner of choice for NORD, collaborating to design and deliver messaging that engages targeted patient and physician communities in rare disease.
The NORD Breakthrough Summit will take place October 19–21, 2025, in Washington, DC, bringing together leaders from across the rare disease community to share insights, build partnerships, and shape the future of education and advocacy.
To learn more about partnering with Medlive on impactful education initiatives, visit our partnerships page.
